Mazdutide Demonstrates Superiority to Semaglutide in Type 2 Diabetes and Obesity
Innovent Biologics, Inc.’s investigative GLP-1/glucagon (GCG) dual receptor agonist mazdutide has met its primary endpoint of superiority to semaglutide in HbA1c and body weight reduction in patients with type 2…